Annonce • Mar 05
Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For Endometriosis Ananda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses. Annonce • Nov 24
Ananda Pharma Plans to Delist from Aquis Stock Exchange Ananda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum". Annonce • Jul 31
Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025 Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom New Risk • May 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$1.0k). Minor Risks Latest financial reports are more than 6 months old (reported July 2024 fiscal period end). Market cap is less than US$100m (€16.6m market cap, or US$18.5m). New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (UK£764 revenue, or US$935). Minor Risk Market cap is less than US$100m (€21.7m market cap, or US$22.4m). Annonce • Dec 11
Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million. Ananda Developments Plc has completed a Follow-on Equity Offering in the amount of £0.15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,857,142
Price\Range: £0.0035 New Risk • Nov 01
New major risk - Negative shareholders equity The company has negative equity. Total equity: -UK£860k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Negative equity (-UK£860k). Earnings have declined by 61% per year over the past 5 years. Revenue is less than US$1m (UK£764 revenue, or US$987). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (€13.8m market cap, or US$15.0m). Annonce • Oct 07
Ananda Developments Plc Announces Appointment of Professor Marie Fallon to Scientific Advisory Board Ananda Developments Plc announced the appointment of Professor Marie Fallon has agreed to join the Company's Scientific Advisory Board to provide the Company with expert technical advice and guidance. The SAB is Chaired by Professor Clive Page, a non-executive director of Ananda Developments plc and it held its first meeting in Edinburgh in May 2024. Prof. Fallon is also the lead investigator for Ananda's Phase II study investigating the pain relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy. Marie Fallon (MD FRCP(Glas) FRCP(E) MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at the University of Edinburgh and is an Honorary Consultant in Palliative Medicine based at the Edinburgh Cancer Centre. Marie has played a significant role in research, leading both national and international research studies around pain and cachexia in cancer patients. Marie has led the development of international palliative care guidelines such as ESMO for cancer pain and ASCO for cachexia. Marie has been Joint Editor of four editions of the Oxford Textbook of Palliative Medicine which is the reference textbook in the specialty. Prof. Fallon has edited several other books and sits on numerous grant committees, as well as being an editorial board member of the BMJ Supportive and Palliative Care journal. Finally, of note, much of Marie's recent and current research relates to Low and Middle Income Countries (LMICs), where she is seeking to address the issue of poor opioid availability in LMICs. New Risk • Sep 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (€14.9m market cap, or US$16.6m). Annonce • Jul 17
Ananda Developments Plc, Annual General Meeting, Aug 09, 2024 Ananda Developments Plc, Annual General Meeting, Aug 09, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v, london United Kingdom New Risk • May 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended July 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported July 2023 fiscal period end). Market cap is less than US$100m (€10.5m market cap, or US$11.4m). New Risk • Nov 01
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended July 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported July 2022 fiscal period end). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (251% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€9.10m market cap, or US$9.61m). Annonce • Aug 01
Ananda Developments Plc, Annual General Meeting, Aug 24, 2023 Ananda Developments Plc, Annual General Meeting, Aug 24, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Shakespeare Martineau Llp, 6th Floor 60 Gracechurch Street, London, EC3V 0HR London United Kingdom Annonce • Dec 20
Ananda Developments plc Announces Board Changes Ananda Developments Plc announced that Stuart Piccaver, the Chief Executive Officer of JEPCO and a director of Anglia Salads, has been appointed as an executive Director of Company. With a background and interest in marketing and innovation, Mr. Piccaver has considerable horticultural experience and direct experience of Cannabis cultivation. Dr. Inbar Pomeranchik, who was previously an executive Director, has become a Non-executive Director of the Company, also with effect from December 19, 2022. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • Jul 21
Ananda Developments Plc, Annual General Meeting, Aug 17, 2022 Ananda Developments Plc, Annual General Meeting, Aug 17, 2022, at 09:00 Coordinated Universal Time. Location: Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United Kingdom Board Change • Jun 06
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.